NASDAQ:EYEN - Eyenovia Stock Price, Forecast & News

Eyenovia trades on the NASDAQ under the ticker symbol "EYEN."

Eyenovia Inc (NASDAQ:EYEN) announced its quarterly earnings results on Wednesday, November, 13th. The company reported ($0.29) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.34) by $0.05. View Eyenovia's Earnings History.

Eyenovia is scheduled to release their next quarterly earnings announcement on Wednesday, March 25th 2020. View Earnings Estimates for Eyenovia.

2 equities research analysts have issued 1 year target prices for Eyenovia's stock. Their forecasts range from $9.00 to $10.00. On average, they anticipate Eyenovia's stock price to reach $9.50 in the next year. This suggests a possible upside of 125.7% from the stock's current price. View Analyst Price Targets for Eyenovia.

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Eyenovia in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Eyenovia.

News stories about EYEN stock have been trending somewhat positive this week, according to InfoTrie Sentiment Analysis. The research group ranks the sentiment of media coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Eyenovia earned a coverage optimism score of 0.8 on InfoTrie's scale. They also assigned news articles about the company a news buzz of 1.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the company's share price in the next several days. View News Stories for Eyenovia.

Eyenovia saw a decrease in short interest during the month of December. As of December 31st, there was short interest totalling 280,300 shares, a decrease of 16.8% from the December 15th total of 336,700 shares. Based on an average trading volume of 94,500 shares, the short-interest ratio is currently 3.0 days. Currently, 2.9% of the shares of the company are short sold. View Eyenovia's Current Options Chain.

Some companies that are related to Eyenovia include Avadel Pharmaceuticals (AVDL), IVERIC bio (ISEE), Geron (GERN), MediciNova (MNOV), Kamada (KMDA), Neptune Wellness Solutions (NEPT), Wave Life Sciences (WVE), Hookipa Pharma (HOOK), Sol Gel Technologies (SLGL), BIOFRONTERA AG/ADR (BFRA), Kala Pharmaceuticals (KALA), Seres Therapeutics (MCRB), Evofem Biosciences (EVFM), MEI Pharma (MEIP) and VBI Vaccines (VBIV).

Based on aggregate information from My MarketBeat watchlists, some companies that other Eyenovia investors own include Zynerba Pharmaceuticals (ZYNE), Axsome Therapeutics (AXSM), ImmunoGen (IMGN), Nabriva Therapeutics (NBRV), Cara Therapeutics (CARA), Fate Therapeutics (FATE), GW Pharmaceuticals PLC- (GWPH), Iovance Biotherapeutics (IOVA), Ovid Therapeutics (OVID) and AbbVie (ABBV).

(EYEN) raised $30 million in an IPO on Thursday, January 25th 2018. The company issued 2,700,000 shares at a price of $10.00-$12.00 per share. Ladenburg Thalmann and Roth Capital Partners​ acted as the underwriters for the IPO.

Shares of EYEN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of EYEN stock can currently be purchased for approximately $4.21.

Eyenovia has a market capitalization of $69.21 million. The company earns $-17,250,000.00 in net income (profit) each year or ($1.82) on an earnings per share basis. View Additional Information About Eyenovia.

The official website for Eyenovia is http://www.eyenoviabio.com/.

Eyenovia's mailing address is 295 Madison Avenue Suite 2400, New York NY, 10017. The company can be reached via phone at 917-289-1117 or via email at [email protected]